TrialFrontiers in immunology2022

PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study.

Yuehong Kong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.